#######################
# Document Properties #
#######################
SET DOCUMENT Copyright = "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses = "Private Ownership to Fraunhofer Institute SCAI"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name = "Neural Systems Governed by Nicotinic Acetylcholine Receptors: Emerging Hypotheses"
SET DOCUMENT Version = "1.0.0"
SET DOCUMENT Description = ""
SET DOCUMENT Authors = "Sandra Spalek"

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns"
DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns"
DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns"
# DEFINE NAMESPACE FB           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/80171ae62cf43aa1fc8a6c326b94537ab342458c/external/fb-names.belns"
DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/56d6631d06deeead416b3b5100d3b4b8d88c29c6/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc.genefamily-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns"
DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mesh-names.belns"
DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns"
DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns"
DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns"
DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns"
DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns"

# Namespaces hosted on https://arty.scai.fraunhofer.de/artifactory/bel/namespace
# ------------------------------------------------------------------------------
DEFINE NAMESPACE CTO            AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns"
DEFINE NAMESPACE DO             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns"
DEFINE NAMESPACE HP             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"
DEFINE NAMESPACE SCOMP          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns"
DEFINE NAMESPACE SFAM           AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
DEFINE NAMESPACE DNSNP          AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############

SET STATEMENT_GROUP = "Sandra"

# Add statements below this comment

SET Citation = {"PubMed", "Neuron. 2011 Apr 14;70(1):20-33. doi: 10.1016/j.neuron.2011.03.014", "21482353"}

SET Evidence = "In 2011, we know that cholinergic actions
in the brain govern various processes: cognition (attention and
executive function) (Couey et al., 2007; Levin and Rezvani,
2007; Heath and Picciotto, 2009; Howe et al., 2010), learning
and memory (Gould, 2006; Couey et al., 2007; Levin and
Rezvani, 2007), mood (anxiety, depression) (Picciotto et al.,
2008), reward (addiction, craving) (Tang and Dani, 2009), and
sensory processing (Heath and Picciotto, 2009)"
SET MeSHAnatomy = "Brain"
bp(GO:"synaptic transmission, cholinergic") -- bp(GO:cognition)
bp(GO:"synaptic transmission, cholinergic") -- bp(GO:learning)
bp(GO:"synaptic transmission, cholinergic") -- bp(GO:memory)
bp(GO:"synaptic transmission, cholinergic") -- path(MESH:Anxiety)
bp(GO:"synaptic transmission, cholinergic") -- path(MESH:Depression)
bp(GO:"synaptic transmission, cholinergic") -- bp(GO:"sensory processing")
UNSET MeSHAnatomy

SET Evidence = "We now realize that acetylcholine liberated from cholinergic
nerve terminals often activates both nAChRs and muscarinic receptors"
a(CHEBI:acetylcholine) -> act(p(FPLX:CHRM))
a(CHEBI:acetylcholine) -> act(p(FPLX:CHRN))

SET Evidence = "A major subtype in the brain is alpha4beta2; the (alpha42beta23) stoichiometry exhibits
at least 10-fold-higher sensitivity than (alpha43beta22), so that only
the former has the high sensitivity (HS) that allows activation
at nicotine concentrations in the 0.1–1 mM range, produced
by moderate tobacco use and by the various nicotine replacement therapies"
SET MeSHAnatomy = "Brain"
a(CHEBI:nicotine) -> complex(p(HGNC:CHRNA4),p(HGNC:CHRNA4),p(HGNC:CHRNB2),p(HGNC:CHRNB2),p(HGNC:CHRNB2))
UNSET MeSHAnatomy

SET Evidence = "alpha7 nAChRs also respond to nicotine concentrations
roughly an order of magnitude higher than alpha42beta23, and alpha7
nAChRs have high Ca2+ permeability resembling that of NMDA receptors"
a(CHEBI:nicotine) -> act(a(MESH:"alpha7 Nicotinic Acetylcholine Receptor"))
bp(GO:"calcium ion transport") -- act(a(MESH:"alpha7 Nicotinic Acetylcholine Receptor"))

SET Evidence = "Most brain HS nAChRs reside on presynaptic terminals,
where they stimulate neurotransmitter release (Gotti et al.,
2006; Albuquerque et al., 2009)"
SET MeSHAnatomy = "Presynaptic Terminals"
p(FPLX:CHRN) -> tloc(a(CHEBI:neurotransmitter),fromLoc(GO:intracellular),toLoc(GO:"extracellular region"))
UNSET MeSHAnatomy

SET Evidence = "The ‘‘volume transmission’’ hypothesis
states that ACh released from presynaptic terminals spreads
to more distant areas, reaching concentrations < 1 mM (Descarries
et al., 1997), but that multiple presynaptic impulses produce
enough summed release to activate receptors (Lester, 2004)"
a(MESH:"Presynaptic Terminals") -> tloc(a(CHEBI:acetylcholine),fromLoc(GO:intracellular),toLoc(GO:"extracellular region"))

SET Evidence = "In most regions that receive cholinergic innervation, the high
density of acetylcholinesterase (which can hydrolyze ACh at
a rate of one per 100 ms!) might vitiate the volume transmission mechanism"
p(HGNC:ACHE) -> deg(a(CHEBI:acetylcholine))

SET Evidence = "As we will see below, the mystery of somatodendritic
nAChRs can also be resolved by the sensitivity of alpha7
nAChRs to constant levels of another agonist, choline"
a(CHEBI:choline) -> act(a(MESH:"alpha7 Nicotinic Acetylcholine Receptor"))

SET Evidence = "Mutations in nicotinic receptor subunits are linked to human disease,
alpha4 and beta2 in some epilepsies, alpha7 in schizophrenia, and alpha5 in
nicotine addiction; and each mutation ultimately manifests itself
as an imbalance in the properties of neuronal circuits"
p(HGNC:CHRNA4,var("?")) positiveCorrelation path(MESH:Epilepsy)
p(HGNC:CHRNB2,var("?")) positiveCorrelation path(MESH:Epilepsy)
p(HGNC:CHRNA7,var("?")) positiveCorrelation path(MESH:Schizophrenia)
p(HGNC:CHRNA5,var("?")) positiveCorrelation path(MESH:"Tobacco Use Disorder")

SET Evidence = "Finally, nAChRs exist in complexes in the brain; interacting proteins engage in
complexes with nAChRs and aid in the assembly and trafficking
of nAChR to the plasma membrane; examples are RIC-3 (Lansdell
et al., 2005), 14-3-3 proteins (Jeanclos et al., 2001), neurexins
(Cheng et al., 2009), and VILIP-1 (Lin et al., 2002)"
SET MeSHAnatomy = "Brain"
complex(p(FPLX:CHRN),p(HGNC:RIC3)) -> p(FPLX:CHRN)
complex(p(FPLX:CHRN),p(HGNC:RIC3)) -> act(p(FPLX:CHRN))
complex(p(FPLX:CHRN),a(INTERPRO:"14-3-3 protein")) -> p(FPLX:CHRN)
complex(p(FPLX:CHRN),a(INTERPRO:"14-3-3 protein")) -> act(p(FPLX:CHRN))
complex(p(FPLX:CHRN),p(INTERPRO:Neurexin)) -> p(FPLX:CHRN)
complex(p(FPLX:CHRN),p(INTERPRO:Neurexin)) -> act(p(FPLX:CHRN))
complex(p(FPLX:CHRN),p(HGNC:VSNL1)) -> p(FPLX:CHRN)
complex(p(FPLX:CHRN),p(HGNC:VSNL1)) -> act(p(FPLX:CHRN))
UNSET MeSHAnatomy

SET Evidence = "Proteins that engage nAChRs within stable
complexes, such as lynx family members, provide a homeostatic
influence over nicotinic receptor systems"
complex(p(FPLX:CHRN),p(HGNC:LYNX1)) reg act(p(FPLX:CHRN))

SET Evidence = "These alpha-neurotoxins are secreted proteins
with sub-nM affinity for nAChRs (Tsetlin et al., 2009) and other
receptors (Auer et al., 2010)"
# these alpha-neurotoxin: alpha-bungarotoxin
complex(p(FPLX:CHRN),a(HBP:"alpha-Bungarotoxin"))

SET Evidence = "As GPI-anchored proteins can bind to transmembrane receptors intracellularly,
the interactions of lynx with nAChRs could potentially
alter receptor trafficking, stoichiometry, and surface number
(Lester et al., 2009)"
complex(p(FPLX:CHRN),p(HGNC:LYNX1)) -- act(p(FPLX:CHRN))
complex(p(FPLX:CHRN),p(HGNC:LYNX1)) -- surf(p(FPLX:CHRN))

SET Evidence = "Therefore, the evolutionary relationship between lynx
modulators and the alpha-neurotoxins agrees with the view that
lynx modulators govern critical control points in the pathway of
nicotinic receptor signaling"
p(HGNC:LYNX1) reg act(p(FPLX:CHRN))

SET Evidence = "Lynx1, the first discovered member of this family expressed in
the brain (Miwa et al., 1999), has an overall inhibitory effect on nAChR function"
SET MeSHAnatomy = "Brain"
p(HGNC:LYNX1) -| act(p(FPLX:CHRN))
UNSET MeSHAnatomy

SET Evidence = "In an alpha4beta2* nAChR-expressing cell, coexpression
of lynx1 results in reduced agonist sensitivity, accelerated
onset of desensitization, and slower recovery from desensitization
(Ibanez-Tallon et al., 2002)"
composite(a(HBP:"alpha-4 beta-2 nAChR"),p(HGNC:LYNX1)) -| act(p(FPLX:CHRN))

SET Evidence = "Each lynx paralog has a relative
binding specificity and modulatory capability on alpha4beta2 (Miwa
et al., 1999; Iban˜ ez-Tallon et al., 2002; Levitin et al., 2008), alpha3
(Arredondo et al., 2006), and alpha7 (Chimienti et al., 2003; Levitin
et al., 2008; Hruska et al., 2009) nAChR subtypes; some interactions
actually enhance nicotinic responses (Chimienti et al.,
2003; Levitin et al., 2008), or their Ca2+ components (Darvas et al., 2009)"
complex(a(HBP:"alpha-4 beta-2 nAChR"),p(HGNC:LYNX1)) reg act(a(HBP:"alpha-4 beta-2 nAChR"))
complex(p(HGNC:LYNX1),p(HGNC:CHRNA3)) reg act(p(HGNC:CHRNA3))
complex(p(HGNC:LYNX1),a(HBP:"alpha-7-containing nAChR")) reg act(a(HBP:"alpha-7-containing nAChR"))

SET Evidence = "Removal of the molecular brake provided by lynx proteins can
lead to nicotinic receptor hypersensitivity—larger direct nicotinic
responses, slowed desensitization kinetics (Miwa et al., 2006),
and enhanced sensitivity of the EPSC frequency in the cortex
to nicotine (Tekinay et al., 2009)"
p(HGNC:LYNX1) -| act(p(FPLX:CHRN))

SET Species = "10090"

SET Evidence = "As a consequence of nAChR
hypersensitivity, lynx1 knockout mice display increased levels
of Ca2+ in neurons, enhancements in synaptic efficacy, and
improved learning and memory functions (Miwa et al., 2006;
Darvas et al., 2009; Tekinay et al., 2009)"
SET MeSHAnatomy = "Neurons"
p(MGI:Lynx1) -| a(CHEBI:"calcium(2+)")
UNSET MeSHAnatomy
p(MGI:Lynx1) -| bp(MESH:"Synaptic Transmission")
p(MGI:Lynx1) -| bp(GO:learning)
p(MGI:Lynx1) -| bp(GO:memory)

SET Evidence = "For instance, adult lynx1KO
mice display heightened ocular dominance plasticity after the
normal close of the critical period (Morishita et al., 2010)"
p(MGI:Lynx1) -| bp(MESH:"Dominance, Ocular")

SET Evidence = "These findings indicate that suppression of the cholinergic system by
lynx proteins stabilizes neural circuitry"
p(MGI:Lynx1) -| bp(GO:"synaptic transmission, cholinergic")
p(MGI:Lynx1) -> a(MESH:Neurons)

UNSET Species

SET Evidence = "Indeed, cholinergic
enhancement (via cholinesterase inhibition) reopens the critical
period for visual acuity in adult wild-type mice (Morishita et al.,
2010), indicating that cellular mechanisms for robust plasticity
are maintained in adulthood through the cholinergic system
but are suppressed by the action of lynx."
act(p(HGNC:ACHE)) -| bp(GO:"synaptic transmission, cholinergic")
p(HGNC:LYNX1) -| bp(GO:"synaptic transmission, cholinergic")

SET Evidence = "Abolishing receptor function through null mutations or pharmacological
blockers of nAChRs abolished some of the gain-offunction
phenotypes in lynx mouse models, indicating that
nAChRs are necessary for the expression of lynx perturbations
(Miwa et al., 2006)"
p(FPLX:CHRN) reg p(HGNC:LYNX1)

SET Evidence = "This indicates that lynx proteins exist, genetically,
as upstream modulators of nicotinic receptor function and
cholinergic signaling and can exert control over cholinergic-dependent processes"
p(HGNC:LYNX1) reg act(p(FPLX:CHRN))

SET Evidence = "Because excess activation of nAChRs
damages neuronal health and brain function, organisms have
a clear need to restrict the degree of nAChR activation"
act(p(FPLX:CHRN)) negativeCorrelation act(a(MESH:Brain))
act(p(FPLX:CHRN)) negativeCorrelation a(MESH:Neurons)

SET Evidence = "Evidence thus far indicates that the lynx family is regulated in
response to relatively strong perturbations: downregulation in
NKCC1 knockout mice (Pfeffer et al., 2009), in adenylyl cyclase
mutant mice (Wieczorek et al., 2010), and by alpha7 nAChR blockade
(Hruska et al., 2009), whereas it is upregulated at the close of the
critical period in the visual cortex, and by nicotine in the lung (Sekhon
et al., 2005)"
SET Species = "10090"
p(MGI:Slc12a2) -> act(p(MGI:Lynx1))
p(FPLX:ADCY,var("?")) -| act(p(MGI:Lynx1))
act(a(MESH:"alpha7 Nicotinic Acetylcholine Receptor")) -> act(p(MGI:Lynx1))
UNSET Species
SET MeSHAnatomy = "Lung"
a(CHEBI:nicotine) -> act(p(MGI:Lynx1))
UNSET MeSHAnatomy

SET Evidence = "While genetic linkages of lynx family members to neurological disorders
have not been found, evidence for cholinergic dysregulation
has been linked to a lynx family member expressed in nonneuronal
tissues and involved in human disease (Chimienti et al.,
2003), and as such, alterations in lynx dosage may be useful in
ameliorating cognitive decline associated with neuropsychiatric disorders."
p(HGNC:LYNX1) -- bp(GO:"synaptic transmission, cholinergic")
p(HGNC:LYNX1) -- path(MESH:"Cognitive Dysfunction")

SET Evidence = "For instance, early expression of lynx1 family member, PSCA,
prevents programmed cell death of parasympathetic neurons
(Hruska et al., 2009)"
SET Cell = "parasympathetic neuron"
p(HGNC:PSCA) -| bp(GO:"programmed cell death")
UNSET Cell

SET Evidence = "Neuronal maturation and loss of synaptic
lability appear to be correlated with the onset of lynx1 expression"
p(HGNC:LYNX1) positiveCorrelation bp(GO:"neuron maturation")
p(HGNC:LYNX1) negativeCorrelation bp(GO:"synapse maturation")

SET Evidence = "The neurodevelopmental program depends in part on alpha7 signaling (Liu et al.,2006)"
bp(GO:"generation of neurons") -- act(a(MESH:"alpha7 Nicotinic Acetylcholine Receptor"))

SET Evidence = "Lynx1 upregulation during a critical neurodevelopmental
period, the switch in the sign of GABAergic signaling, and
coexpression of lynx with GABAergic subsets all indicate a
possible role of lynx mediating the timing of such developmental transitions"
p(HGNC:LYNX1) reg bp(GO:"generation of neurons")

SET Evidence = "Nicotinic receptor control over GABAergic neuronal
development and mature activity may represent a point of
convergence for diseases such as schizophrenia (see next
section), some amblyopias (Bavelier et al., 2010), and some
epilepsies (Klaassen et al., 2006), which distort the excitatory-inhibitory
balance in general and implicate GABAergic signaling defects in particular"
p(FPLX:CHRN) reg bp(GO:"GABAergic neuron differentiation")
bp(GO:"GABAergic neuron differentiation") -- path(MESH:Schizophrenia)
bp(GO:"GABAergic neuron differentiation") -- path(MESH:Amblyopia)

SET Evidence = "Developmental changes in nAChR functions
may play a role in nicotine addiction, as a central question in
tobacco control is young adult smokers’ marked sensitivity to
developing nicotine dependence (DSM-V Nicotine Workgroup,
2010; DiFranza et al., 2000; Difranza, 2010)"
act(p(FPLX:CHRN)) -- path(MESH:"Tobacco Use Disorder")

SET Evidence = "In many persons with schizophrenia, cerebral evoked potential recording shows
diminished inhibition of the response to repeated stimuli (Adler
et al., 1982) (Figure 2A), and animal models of this phenomenon
point to a defect in hippocampal inhibition"
path(MESH:Schizophrenia) -> act(a(MESH:Hippocampus))

SET Evidence = "Recent studies provide evidence both that nicotinic signaling partially underlies
these schizophrenia-related inhibitory defects and that nicotinic drugs have possible therapeutic roles"
act(p(FPLX:CHRN))  -- path(MESH:Schizophrenia)

SET Evidence = "alpha7 nAChRs on inhibitory interneurons
throughout the hippocampus and presynaptic alpha7 nAChRs on
mossy fiber terminals in the dentate gyrus participate in the
control of sensory response in the hippocampus (Gray et al.,
1996; Alkondon et al., 1999"
SET MeSHAnatomy = {"Dentate Gyrus","Hippocampus"}
a(MESH:"alpha7 Nicotinic Acetylcholine Receptor") reg bp(GO:"sensory processing")
a(HP:"inhibitory interneuron") reg bp(GO:"sensory processing")
UNSET MeSHAnatomy

SET Evidence = "Nicotinic activation of inhibitory
interneurons increases their activity and activates nitric oxide synthetase"
p(FPLX:CHRN) -> act(a(HP:"inhibitory interneuron"))
act(a(HP:"inhibitory interneuron")) -> act(p(FPLX:NOS))
p(FPLX:CHRN) -> act(p(FPLX:NOS))

SET Evidence = "The neurons release additional GABA, activating
presynaptic GABAB receptors on the excitatory inputs to pyramidal
neurons, which diminish the release of glutamate onto the pyramidal neurons (Figure 2)"
a(MESH:Neurons) -> tloc(a(CHEBI:"gamma-aminobutyric acid"),fromLoc(GO:intracellular),toLoc(GO:"extracellular region"))
SET MeSHAnatomy = "Pyramidal Cells"
a(CHEBI:"gamma-aminobutyric acid") -> act(p(HGNC:GABBR1))
a(CHEBI:"gamma-aminobutyric acid") -> act(p(HGNC:GABBR2))
a(CHEBI:"gamma-aminobutyric acid") -| tloc(a(CHEBI:"glutamate(2-)"),fromLoc(GO:intracellular),toLoc(GO:"extracellular region"))
UNSET MeSHAnatomy

SET Evidence = "Thus, the brainstem can regulate hippocampal response in the presence
of high sensory input."
a(MESH:"Brain Stem") reg act(a(MESH:Hippocampus))

SET Evidence = "Although alpha7 nAChRs have both presynaptic
and postsynaptic expression (Frazier et al., 1998), their
postsynaptic expression in humans is especially marked on
inhibitory neurons of the hippocampus (Alkondon et al., 2000)"
SET MeSHAnatomy = "Hippocampus"
a(MESH:"alpha7 Nicotinic Acetylcholine Receptor") -- a(HP:"inhibitory interneuron")
UNSET MeSHAnatomy

SET MeSHDisease = "Schizophrenia"

SET Evidence = "Three lines of evidence support the possibility that the failure
of sensory inhibition in schizophrenia results from decreased expression of alpha7 nAChRs"
a(MESH:"alpha7 Nicotinic Acetylcholine Receptor") -> bp(GO:"sensory processing")

SET Evidence = "First, postmortem studies of the
hippocampus and thalamus show diminished labeling of putative
inhibitory neurons by alpha-bungarotoxin, an antagonist of alpha7
nAChRs (Court et al., 1999)"
a(HBP:"alpha-Bungarotoxin") -> act(a(MESH:"alpha7 Nicotinic Acetylcholine Receptor"))
a(MESH:"alpha7 Nicotinic Acetylcholine Receptor") -> a(HP:"inhibitory interneuron")

SET Evidence = "Polymorphisms in the alpha7 5' promoter
and in a nearby partial duplication of the gene, FAM7A, are
associated with both schizophrenia and the defect in inhibition
(Leonard et al., 2002)"
g(HGNC:CHRFAM7A, var("?")) -- path(MESH:Schizophrenia)
g(HGNC:CHRFAM7A, var("?")) negativeCorrelation act(a(HP:"inhibitory interneuron"))

SET Evidence = "Yet some of the other genes identified, such as NRG1, are involved in the
assembly of alpha7 nAChRs, further supporting a potential link
between alpha7 nAChRs and schizophrenia (Mathew et al., 2007)"
g(HGNC:NRG1) -> a(MESH:"alpha7 Nicotinic Acetylcholine Receptor")
a(MESH:"alpha7 Nicotinic Acetylcholine Receptor") -- path(MESH:Schizophrenia)

SET Evidence = "Third, persons with schizophrenia have the greatest rate and
intensity of cigarette smoking of any identifiable subgroup in
the population"
path(MESH:Schizophrenia) positiveCorrelation path(MESH:"Tobacco Use Disorder")

SET Evidence = "While it is not yet possible to know precisely how well a7 nAChRs are activated
by smoked nicotine, one can reasonably hypothesize that
the patients’ higher dose of nicotine activates alpha7 nAChRs (Adler
et al., 1993; Papke and Thinschmidt, 1998; Royal College of Physicians, 2007)"
a(CHEBI:nicotine) -> act(a(MESH:"alpha7 Nicotinic Acetylcholine Receptor"))

SET Evidence = "3-(2,4 dimethoxy)-benzylidene-anabaseine, derived from an
alkaloid produced by nemertine worms, is a partial agonist at alpha7 nAChRs"
a(HBP:"GTS-21") -> act(a(MESH:"alpha7 Nicotinic Acetylcholine Receptor"))

SET Evidence = "It improves sensory inhibition in schizophrenics
and also moderately improves their neuropsychological deficits
in attention (Olincy et al., 2006)"
# it: 3-(2,4-dimethoxybenzylidene)anabaseine
a(HBP:"GTS-21") -> path(MESH:Attention)
a(HBP:"GTS-21") -> bp(GO:"sensory processing")

SET Evidence = "Clinical ratings of their negative
symptoms, particularly anhedonia (absence of a sense of pleasure)
and alogia (poverty of content in their speech), also improve
during treatment"
a(HBP:"GTS-21") -| path(MESH:Anhedonia)
a(HBP:"GTS-21") -| path(MESH:Aphasia)

UNSET MeSHDisease

SET Evidence = "One important role for alpha7 nAChRs, in conjunction
with alpha3-containing nAChRs, is the induction of the KCC2
chloride transporter in pyramidal neurons (Liu et al., 2006)"
SET MeSHAnatomy = "Pyramidal Cells"
a(HBP:"alpha-7-containing nAChR") -> p(HGNC:SLC12A5)
UNSET MeSHAnatomy

SET Evidence = "This transporter lowers the internal Cl- concentration of the neuron
and changes GABA from a depolarizing to a hyperpolarizing or inhibitory neurotransmitter"
#this transporter: SLC12A5
SET MeSHAnatomy = "Neurons"
p(HGNC:SLC12A5) -| a(CHEBI:chloride)
p(HGNC:SLC12A5) reg act(a(CHEBI:"gamma-aminobutyric acid"))
UNSET MeSHAnatomy

SET Evidence = "A specific role of alpha7 nAChRs was
demonstrated by failure of the induction of KCC2 by treatment
with alpha7 nAChR antagonists and in a7 KO mice (Zhang and Berg, 2007)"
a(HBP:"alpha-7-containing nAChR") -> p(HGNC:SLC12A5)

SET Evidence = "A possible candidate is choline, which, in
addition to its other development roles, activates alpha7 nAChRs at
levels several fold higher than acetylcholine"
a(CHEBI:acetylcholine) -> act(a(HBP:"alpha-7-containing nAChR"))
a(CHEBI:choline) -> act(a(HBP:"alpha-7-containing nAChR"))

SET Evidence = "Variants in the gene for phosphatidylethanolamine methyl transferase, which
synthesizes phosphatidylcholine and thus provides a source of
choline, are also associated with choline deficiency and with schizophrenia"
p(HGNC:PEMT) -> a(CHEBI:phosphatidylcholine)
a(CHEBI:phosphatidylcholine) -> a(CHEBI:choline)
p(HGNC:PEMT,var("?")) -- path(MESH:"Choline Deficiency")
p(HGNC:PEMT,var("?")) -- path(MESH:Schizophrenia)

SET Evidence = "alpha7 nAChRs are involved in the macrophage and
placental cytokine response, which may be an additional role
for genetic variants in these receptors in the pathogenesis of
schizophrenia (Wang et al., 2003)"
a(HBP:"alpha-7-containing nAChR") -- bp(GO:"macrophage activation")
SET MeSHAnatomy = "Placenta"
a(HBP:"alpha-7-containing nAChR") -- bp(GO:"response to cytokine")
UNSET MeSHAnatomy

SET Evidence = "Nicotine both activates and desensitizes
nAChRs in midbrain dopaminergic neurons (Brodie, 1991; Pidoplichko
et al., 1997), and the pleasurable effects associated with
nicotine intake occur in large part via the mesolimbic dopaminergic
reward system (Corrigall et al., 1992; Koob and Volkow,2010)"
SET MeSHAnatomy = "Dopaminergic Neurons"
a(CHEBI:nicotine) -> act(p(FPLX:CHRN))
UNSET MeSHAnatomy

SET Evidence = "However, it is not known whether the nicotine-enhanced
cognitive performance exceeds the level that would occur if the
person had never begun to smoke, or after remaining abstinent
for one year (the usual criterion for successful smoking cessation)
(Levin et al., 2006)"
a(CHEBI:nicotine) -> bp(GO:cognition)

SET Evidence = "In rodents and humans, the hippocampus is
importantly implicated in cognitive sensitization, and alpha4beta2*
nAChRs play key roles (Levin et al., 2006; Davis and Gould, 2009)"
a(HBP:"alpha-4 beta-2 nAChR") positiveCorrelation bp(GO:cognition)

SET Evidence = "Chronic or acute nicotine enhances LTP in several regions
of hippocampus, especially dentate gyrus (Nashmi et al., 2007;
TangandDani, 2009;Pentonet al., 2011)"
SET MeSHAnatomy = {"Dentate Gyrus","Hippocampus"}
a(CHEBI:nicotine) -> bp(GO:"long-term synaptic potentiation")
UNSET MeSHAnatomy

SET Evidence = "For instance, dopamine increases in the extended
amygdala during stress, fear, and nicotine withdrawal (Inglis
and Moghaddam, 1999; Pape, 2005; Grace et al., 2007;
Gallagher et al., 2008; Koob, 2009; Marcinkiewcz et al., 2009)"
SET MeSHAnatomy = "Amygdala"
bp(MESH:"Stress, Physiological") -> a(CHEBI:dopamine)
path(MESH:Fear) -> a(CHEBI:dopamine)
a(CHEBI:nicotine) -| a(CHEBI:dopamine)
UNSET MeSHAnatomy

SET Evidence = "This puzzle does not yet have a complete answer, but it is
clear that chronic nicotine increases the number of nAChRs
themselves (Marks et al., 1983; Schwartz and Kellar, 1983)"
a(CHEBI:nicotine) -> p(FPLX:CHRN)

SET Evidence = "At the level of whole brain, chronic nicotine causes selective
upregulation of nAChRs among major brain regions. Upregulation
occurs in cortex, midbrain, and hypothalamus, but not in
thalamus or cerebellum (Pauly et al., 1991; Marks et al., 1992;
Nguyen et al., 2003; Nashmi et al., 2007; Doura et al., 2008)"
SET MeSHAnatomy = {"Cerebral Cortex","Mesencephalon","Hypothalamus"}
a(CHEBI:nicotine) -> p(FPLX:CHRN)
SET MeSHAnatomy = {"Thalamus","Cerebellum"}
a(CHEBI:nicotine) causesNoChange p(FPLX:CHRN)
UNSET MeSHAnatomy

SET Evidence = "In the midbrain, both DA neurons (in substantia
nigra pars compacta and ventral tegmental area [VTA]) and
GABAergic neurons (in substantia nigra pars reticulata and
VTA) express high levels of alpha4beta2* nAChRs on their somata, but
only GABAergic neurons display somatic upregulation (Nashmi
et al., 2007; Xiao et al., 2009)"
SET MeSHAnatomy = {"Mesencephalon","Ventral Tegmental Area","Pars Compacta"}
a(MESH:"Dopaminergic Neurons") positiveCorrelation a(HBP:"alpha-4 beta-2 nAChR")
SET MeSHAnatomy = {"Mesencephalon","Ventral Tegmental Area","Pars Reticulata"}
a(MESH:"GABAergic Neurons") positiveCorrelation a(HBP:"alpha-4 beta-2 nAChR")
UNSET MeSHAnatomy

SET Evidence = "In the medial perforant path, which
mainly arises from layer II stellate cells, chronic nicotine upregulates alpha4beta2* nAChRs"
SET MeSHAnatomy = {"Entorhinal Cortex","Dentate Gyrus"}
a(CHEBI:nicotine) -> act(a(HBP:"alpha-4 beta-2 nAChR"))
UNSET MeSHAnatomy

SET Evidence = "In midbrain, chronic nicotine treatment elicits
a general increase in alpha4beta2* nAChRs in GABAergic neurons, but
only in axon terminals of DA neurons"
SET MeSHAnatomy = {"Mesencephalon","GABAergic Neurons"}
a(CHEBI:nicotine) -> act(a(HBP:"alpha-4 beta-2 nAChR"))
UNSET MeSHAnatomy

SET Evidence = "Single-nucleotide polymorphisms found in the human alpha5, alpha3,
beta4 gene cluster are associated with nicotine dependence and
its age-dependent onset; number of cigarettes smoked per
day and ‘‘pleasurable buzz’’ elicited by smoking; alcoholism,
sensitivity to the depressant effects of alcohol, and age of
alcohol initiation; cocaine dependence; opioid dependence;
lung cancer; and cognitive flexibility (Erlich et al., 2010; Hansen
et al., 2010; Improgo et al., 2010; Saccone et al., 2010; Zhang et al., 2010)"
p(HGNC:CHRNA5,var("?")) positiveCorrelation path(MESH:"Tobacco Use Disorder")
p(HGNC:CHRNA5,var("?")) positiveCorrelation path(MESH:Alcoholism)
p(HGNC:CHRNA5,var("?")) positiveCorrelation path(MESH:"Cocaine-Related Disorders")
p(HGNC:CHRNA5,var("?")) positiveCorrelation path(MESH:"Opioid-Related Disorders")
p(HGNC:CHRNA5,var("?")) positiveCorrelation path(MESH:"Lung Neoplasms")
p(HGNC:CHRNA5,var("?")) positiveCorrelation bp(GO:cognition)
p(HGNC:CHRNA3,var("?")) positiveCorrelation path(MESH:"Tobacco Use Disorder")
p(HGNC:CHRNA3,var("?")) positiveCorrelation path(MESH:Alcoholism)
p(HGNC:CHRNA3,var("?")) positiveCorrelation path(MESH:"Cocaine-Related Disorders")
p(HGNC:CHRNA3,var("?")) positiveCorrelation path(MESH:"Opioid-Related Disorders")
p(HGNC:CHRNA3,var("?")) positiveCorrelation path(MESH:"Lung Neoplasms")
p(HGNC:CHRNA3,var("?")) positiveCorrelation bp(GO:cognition)
p(HGNC:CHRNB4,var("?")) positiveCorrelation path(MESH:"Tobacco Use Disorder")
p(HGNC:CHRNB4,var("?")) positiveCorrelation path(MESH:Alcoholism)
p(HGNC:CHRNB4,var("?")) positiveCorrelation path(MESH:"Cocaine-Related Disorders")
p(HGNC:CHRNB4,var("?")) positiveCorrelation path(MESH:"Opioid-Related Disorders")
p(HGNC:CHRNB4,var("?")) positiveCorrelation path(MESH:"Lung Neoplasms")
p(HGNC:CHRNB4,var("?")) positiveCorrelation bp(GO:cognition)

SET Evidence = "Because alpha4beta2 nAChRs are
the most susceptible to nicotine-induced upregulation, the
data again seem consistent with the idea that selective upregulation
of alpha4beta2 nAChRs underlies nicotine dependence"
a(CHEBI:nicotine) -> act(a(HBP:"alpha-4 beta-2 nAChR"))
path(MESH:"Tobacco Use Disorder") -> act(a(HBP:"alpha-4 beta-2 nAChR"))

SET Evidence = "The upregulation of alpha4beta2*
nAChRs by chronic nicotine treatment has been replicated
many times in numerous systems—transfected cell lines,
neurons in culture, brain slices, and smokers’ brains (Albuquerque
et al., 2009; Fu et al., 2009; Lester et al., 2009; Srinivasan et al., 2011"
a(CHEBI:nicotine) -> act(a(HBP:"alpha-4 beta-2 nAChR"))

SET Evidence = "(3) Nicotine activates alpha4beta2 nAChRs ~400-fold more effectively
than it activates muscle-type nAChRs, because of cation-π
and H-bond interactions at the agonist binding site (Xiu et al., 2009)"
a(CHEBI:nicotine) -> act(a(HBP:"alpha-4 beta-2 nAChR"))

SET Evidence = "However, when all genetic factors are eliminated by studying
monozygotic twins who are discordant for both tobacco use
and Parkinson’s disease, tobacco smoking and chewing still
decrease the risk of Parkinson’s disease (Tanner et al., 2002; Wirdefeldt et al., 2005)"
path(MESH:Smoking) -| path(MESH:"Parkinson Disease")
path(MESH:"Tobacco Use") -| path(MESH:"Parkinson Disease")

SET Species = "10090"

SET Evidence = "While chronic nicotine does not change the abundance or function of alpha4*
nAChRs in the somata of substantia nigra pars compacta dopaminergic
neurons, it does suppress baseline firing rates of these DA neurons."
SET MeSHAnatomy = "Pars Compacta"
a(CHEBI:nicotine) causesNoChange a(HBP:"alpha-4-containing nAChR")
a(CHEBI:nicotine) -| act(a(MESH:"Dopaminergic Neurons"))
UNSET MeSHAnatomy

SET Evidence = "In mice exposed to chronic nicotine, GABA neurons
in substantia nigra pars reticulata have increased baseline firing
rates, both in brain slices and in anesthetized animals"
SET MeSHAnatomy = "Pars Reticulata"
a(CHEBI:nicotine) -> act(a(MESH:"GABAergic Neurons"))
UNSET MeSHAnatomy

UNSET Species

SET Evidence = "These contrasting effects on GABA and DA neurons are due to upregulated
alpha4* nAChR responses in GABA neurons, at both somata and synaptic terminals"
SET MeSHAnatomy = "GABAergic Neurons"
a(CHEBI:nicotine) -> act(a(HBP:"alpha-4-containing nAChR"))
UNSET MeSHAnatomy

SET Evidence = "Chronic nicotine upregulates alpha4*
nAChRs in dopaminergic presynaptic terminals, apparently
leading to increased resting dopamine release from those terminals"
SET MeSHAnatomy = {"Presynaptic Terminals","Dopaminergic Neurons"}
a(CHEBI:nicotine) -> act(a(HBP:"alpha-4-containing nAChR"))
a(CHEBI:nicotine) -> tloc(a(CHEBI:dopamine),fromLoc(MESH:"Presynaptic Terminals"),toLoc(GO:"extracellular region"))
UNSET MeSHAnatomy

SET Evidence = "The chaperoning of nAChRs by nicotine
enhances the export of alpha4beta2 nAChRs from the endoplasmic
reticulum (ER), and this leads to a general increase in ER exit
sites (Srinivasan et al., 2011)"
a(CHEBI:nicotine) -> tloc(a(HBP:"alpha-4-containing nAChR"),fromLoc(GO:"endoplasmic reticulum"),toLoc(GO:"extracellular region"))

SET Evidence = "Autosomal-dominant nocturnal frontal lobe epilepsy (ADNFLE) is
caused by missense mutations in either the alpha4 or the beta2 subunit"
p(HGNC:CHRNA4,var("?")) -> path(HBP:"Autosomal Dominant Nocturnal Frontal Lobe Epilepsy")
p(HGNC:CHRNB2,var("?")) -> path(HBP:"Autosomal Dominant Nocturnal Frontal Lobe Epilepsy")

SET Evidence = "ADNFLE patients who use a nicotine patch or tobacco have fewer seizures
(Willoughby et al., 2003; Brodtkorb and Picard, 2006)"
a(CHEBI:nicotine) -| path(HBP:"Autosomal Dominant Nocturnal Frontal Lobe Epilepsy")


##########################################################


UNSET STATEMENT_GROUP
